Procept Biorobotics Corp
NASDAQ:PRCT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
Procept Biorobotics Corp
NASDAQ:PRCT
|
US |
|
C
|
Chugai Pharmaceutical Co Ltd
DUS:CUP
|
JP |
|
Image Resources NL
ASX:IMA
|
AU |
|
MegaPower Makmur Tbk PT
IDX:MPOW
|
ID |
|
Lithium Americas Corp
F:WUC
|
CA |
|
G
|
Gap Inc
F:GAP
|
US |
|
I
|
Impala Platinum Holdings Ltd
JSE:IMP
|
ZA |
|
West High Yield (WHY) Resources Ltd
XTSX:WHY
|
CA |
Intrinsic Value
Is PRCT undervalued or overvalued?
See the intrinsic value estimate for Procept Biorobotics Corp and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
PRCT looks undervalued.
But is it cheap by its own standards?
See how today’s valuation compares with PRCT’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Procept Biorobotics Does
Procept BioRobotics makes robotic medical devices for treating enlarged prostate, a common condition in older men. Its main product is the AQUABEAM system, which helps urologists remove extra prostate tissue using a precise waterjet guided by imaging and robotics. The company’s tools are used in hospitals and outpatient surgery centers where doctors perform these procedures.
- Headquarters
- United States of America US
- Employees
- 888
- IPO date
- Sep 15, 2021
Procept Biorobotics has no economic moat
Procept Biorobotics Corp lacks an economic moat, leaving it vulnerable to competitive pressures and market challenges.
Read the full moat analysis
Earnings Waterfall
Procept Biorobotics Corp
The intrinsic value for Procept Biorobotics Corp (PRCT) under the Base Case is hidden USD.
Compared with the current market price of 19.44 USD, the stock appears hidden.